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Abstract Sudden cardiac death due to ventricular arrhyth-
mias is a major problem. Drug therapies to prevent SCD do
not provide satisfying results, leading to the demand for new
antiarrhythmic strategies. New targets include Ca2+/Calmod-
ulin-dependent protein kinase II (CaMKII), the Na/Ca ex-
changer (NCX), the Ryanodine receptor (RyR, and its associ-
ated protein FKBP12.6 (Calstabin)) and the late component of
the sodium current (INa-Late), all related to intracellular calcium
(Ca2+) handling. In this review, drugs interfering with these
targets (SEA-0400, K201, KN-93, W7, ranolazine,
sophocarpine, and GS-967) are evaluated and their future as
clinical compounds is considered. These new targets prove to
be interesting; however more insight into long-term drug
effects is necessary before clinical applicability becomes
reality.
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Introduction
Sudden cardiac death (SCD) due to arrhythmias is a major
problem in theWestern population [1]. SCD occurs when, due
to a trigger, sinus rhythm lapses into ventricular tachycardia
(VT) which can deteriorate into ventricular fibrillation. At that
stage of rhythm disorder, the contractile performance of the
heart is severely compromised and eventually results in
asystole and, as such, arrest of effective circulation [2]. Con-
ditions such as congenital heart disease, cardiomyopathies and
risk factors (e.g. smoking or hypertension) can be the
underlying mechanisms of SCD [2]. In patients with dilated
cardiomyopathy 30 % will suffer from SCD [3]. SCD in
patients with end-stage heart failure is mostly due to mechan-
ical dysfunction based on structural and contractile changes
[3]. Prevention strategies focus on antiarrhythmic drugs and
implantation of a cardiac defibrillator. Current drug therapies,
though effective, also have major drawbacks (as discussed
below) and the results have partially been disappointing [4].
Besides the classical modulation of sarcolemmal ion chan-
nels by drugs (including both activation and block), new
antiarrhythmic targets emerge that can be of great interest in
pharmacological treatment of VT in cardiac disease. Especial-
ly arrhythmias that occur in hypertrophy and heart failure have
our attention, because of the difficulty in treating these pa-
tients effectively. Besides disappointing data concerning anti-
arrhythmic efficacy, current therapies such as blockade of the
late-type calcium current (ICa-L), are known to affect
haemodynamics negatively.
These new targets include Ca2+/Calmodulin-dependent
protein kinase II (CaMKII), the Na/Ca exchanger (NCX),
the Ryanodine receptor (RyR, and its associated protein
FKBP12.6) and the late component of the sodium current
(INa-Late), all related to intracellular calcium (Ca
2+) handling
of the cardiac myocyte. With this development, emphasis of
antiarrhythmic drugs seems to shift therapy more in the direc-
tion of focal arrhythmias, which can be caused by delayed
(DAD) or early after depolarisations (EAD), a logical step
knowing that triggered activity-related arrhythmias are be-
coming more and more common in hypertrophy and heart
failure [5].
Impulse propagation
For the heart to function properly, excitation and contraction
of all myocytes in the heart needs to be coordinated and
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balanced. Therefore the electrical impulse that initiates exci-
tation moves throughout the heart via a specific route starting
in the sinoatrial node. Next the atria are activated, after which
the electrical signal passes the atrioventricular node and
travels down through the bundle of His and the bundle
branches towards the apex of the heart. From there it activates
the ventricular myocytes from apex to base via the network of
Purkinje fibres and this is further supported by the anisotropic
fibre structure. This sequence leads to a coordinated contrac-
tion of the ventricles. For the signal to travel from myocyte to
myocyte they need to be coupled electrically. This electrical
and metabolic coupling of myocytes is facilitated by gap
junctions that are built from connexin proteins (Cxs). In the
heart three isoforms of Cxs are present. Cx40 is mainly
expressed in the atria and throughout the conduction system.
Cx43 is the most abundant Cx isoform in both the atria and
ventricles but is also found in the distal conduction pathway.
Finally, Cx45 is only found in the nodes, the His bundle, and
bundle branches [6]. For a detailed review of cardiac
connexins see Jansen et al. [6]. The Cxs are localised in the
intercalated disks between the myocytes. It is this localisation
that facilitates that conduction is anisotropic with a faster
conduction along the fibre length (longitudinal conduction)
compared with the conduction perpendicular to that given
orientation (transverse conduction).
Remodelling of the highly homogeneous expression pat-
tern of Cxs during disease may contribute to generation of a
proarrhythmic substrate which may increase the propensity
for re-entry based arrhythmias. Re-entry based arrhythmias
are, however, beyond the scope of this review. In addition,
focal uncoupling of the electrical syncytium may favour the
occurrence of ectopic activity. The mechanisms that underlie
ectopic activity will be further discussed and provide potential
new targets for antiarrhythmic interference.
Impulse generation and contraction
Ions→ action potential duration (APD)
The action potential (AP) is generated via a complex interac-
tion of ion channels, and membrane voltage [7], and is gener-
ally divided into five phases. They are established through a
fine-tuned interaction of sodium (Na+), potassium (K+), and
Ca2+ currents. The inward Na+ current (INa) is responsible for
the upstroke during phase 0 (Fig. 1, phase 0). The total Na+
current is formed by the peak and late INa: the latter contrib-
utes to depolarisation currents during the plateau phase. Dur-
ing phase 1, the Na+ channel inactivates considerably and at
the same time Ito1 and Ito2 (transient outward currents) create
outward currents of K+ and chloride, respectively, to form the
notch (Fig. 1, phase 1). Subsequently, Ca2+ enters the cell
through voltage-gated Ca2+channels (L-type calcium
channels, LTCC) (ICa,L) and is involved in creating the plateau
phase of the AP since inward movement of Ca2+ is
counterbalanced by outward K+ flow driven by the delayed
rectifier potassium currents IKs and IKr (Fig. 1, phase 2). The
plateau phase delays repolarisation of the AP creating time for
contraction and relaxation of the cardiomyocytes in between
action potentials. Full repolarisation occurs when the LTCC
closes and IKs and IKr take over dominantly (Fig. 1, phase 3).
Finally, K+ restores the negative membrane potential via the
IK1 current (Fig. 1, phase 4) [7].
Excitation-contraction coupling
Of the ions involved in the activation of the heart, Ca2+
plays a key role in excitation-contraction. As mentioned,
Ca2+ has effects on the membrane potential during the
AP plateau via LTCC. LTCC is activated upon
depolarisation of the sarcolemma due to a local increase
of positive charge that is brought about through influx
of [Na+], while LTCC is inactivated by local [Ca2+]i via
calmodulin (CaM) binding on the C-terminus of the
channel. The initial Ca2+ influx via the LTCC leads to
Ca2+ induced calcium release (CICR) from the sarco-
plasmic reticulum (SR), which is mediated by the RyRs
(reviewed by Bers [8]). When RyR is activated, this
leads to Ca2+ extrusion from the SR thereby increasing
[Ca2+]i but this increase in Ca
2+ also triggers inactiva-
tion of the LTCC. The RyR is a channel, but also a
scaffolding protein that clusters proteins such as CaM
(exerts Ca2+ dependent modulation of RyR and LTCC
function, see below), protein kinase A (PKA, which can
alter RyR and Ica gating), and sorcin (which connects
RyRs and LTCCs) near the Ca2+ release complex. Sub-
sequently, Ca2+ released from the SR binds to troponin
to facilitate contraction of the sarcomere, the contractile
element of the myocyte. Thus, Ca2+ links the electrical
activation of cardiomyocytes to mechanical contraction:
excitation-contraction coupling (Fig. 2).
During relaxation, free cytoplasmic Ca2+ must decline to
allow Ca2+ to dissociate from troponin leading to relaxation of
the contractile element. This Ca2+ transport is facilitated by a
Ca2+-ATPase (SERCA) on the SR which transports Ca2+ back
into the SR and the NCX on the sarcolemma [8]. SERCA is an
active Ca2+ pump whose activity is controlled by the phos-
phorylation status of phospholamban (PLN). When certain
residues on PLN are not phosphorylated, SERCA activity is
inhibited but this inhibition is relieved when PLN becomes
phosphorylated by PKA. Activators of PKA, such as β-
adrenergic stimulation, can therefore play a role in relaxation,
as more Ca2+ is restored in the SR because of higher SERCA
activity. This, in turn, renders more Ca2+ available for CICR in
the subsequent beats which results in a stronger force of
contraction.
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The NCX on the sarcolemma exchanges three Na+ ions for
one Ca2+ ion. This exchange generates an electrical current
that can go in both directions and is dependent on the [Na+]
and [Ca2+] across the sarcolemma as well as the membrane
potential. Whether the current is in the forward or reversed
mode depends on the driving force for NCX. High [Ca2+]i
favours forward INa/Cawhereas high [Na
+]i and positive mem-
brane potential favours reversed INa/Ca [8].
Fig. 2 Calcium handling. 0;
Sodium enters the cell, creating
the AP upstroke. 1; Calcium
enters via the LTCC facilitating
the plateau phase of the AP and
initiating CICR. 2; via RyR on the
sarcoplasmic reticulum leading to
3; calcium binding to the
contractile elements: excitation-
contraction coupling. 4; NCX
transports calcium from the cell in
exchange for sodium. 5; calcium
is pumped back into the SR via
SERCA, together with 4 this leads
to relaxation of the contractile
elements and the end of the
plateau phase. 6; Potassium
restores the negative membrane
potential
Fig. 1 Action potential and ion
currents. Phases of the action
potential and the responsible ion
currents are discussed in the text
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Arrhythmias: abnormal excitation
Triggered arrhythmias
In hypertrophy and heart failure, Ca2+ handling is disturbed.
As has been shown in several models, functional expression
of SERCA is reduced whereas activity of the NCX is in-
creased [5, 8]. Moreover, kinetics of RyR openings are also
changed, leading to unanticipated Ca2+releases that can initi-
ate EADs and DADs (Fig. 3). They are defined as: oscillations
that attend (EADs) or follow (DADs) the cardiac AP and
respond to preceding activation for their manifestation [9].
When the amplitude of the depolarisation reaches threshold,
triggered activity in the form of ectopic beats occurs.
DADs
DADs arise after full repolarisation of the myocyte. Ca2+
release from the SR is triggered when free SR [Ca2+],
([Ca2+]SR), reaches a certain threshold leading to opening of
RyRs (Fig. 4) [10]. [Ca2+]SR is influenced by total [Ca
2+]i and
the activity of SERCA. Increased [Ca2+]SR load due to higher
SERCA activity, for example via β-adrenergic stimulation,
brings the [Ca2+]SR closer to the threshold for SR leak. Fur-
thermore, the threshold is affected by the RyR open probabil-
ity: if the open probability increases, the threshold lowers. The
open probability of RyR is modulated by [Ca2+]SR, [Ca
2+]i,
AP, RyR phosphorylation and the stabilising protein
FKBP12.6 (Calstabin) [11, 12]. RyR phosphorylation is
among others executed by CaMKII, and this increases the
open probability of RyR [13, 14]. Opening of multiple RyRs
creates Ca2+ sparks, which can lead to DADs via creation of
the transient inward current (Iti) by the NCX (Fig. 3) [15]. If
the DADs reach threshold a new AP arises. In heart failure,
[Ca2+]SR and threshold are both lowered (Fig. 4) yet threshold
is affected more than [Ca2+]SR leading to a higher occurrence
of triggered arrhythmias in these patients [16].
EADs
EADs are generated in the ventricle during phase 2 or phase 3
of the AP, and can occur during prolongation of AP duration
(APD) via a window current of the LTCC (Fig. 3) [9, 17].
However, also NCX plays a role in EAD formation in a mode
Fig. 3 a EAD and DAD
formation. SR calcium overload
leads to increased [Ca2+]i. This
can lead to prolonged action
potential duration creating a
calcium window current
potentially leading to EAD (3).
Increased [Ca2+]i on the other
hand can lead to spontaneous
calcium release via CICR
resulting in either EADs (4) or
DADs (2) via NCX. Also, late Ina
is able to increase [Ca]i via NCXr,
hereby contributing to EAD
formation. Numbers
corresponding to black numbers
in b. b 1; normal action potential
and ICaL and INCX. 2; DAD
occurring due to forward NCX
activity (*). 3; EAD due to
calcium window current via
LTCC (**). 4; EAD due to
forward NCX activity (***)
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which is comparable with that as described for DADs. This
indicates that EAD formation can occur via two routes, name-
ly a sarcolemmal (LTCC) and an SR (RyR and NCX) depen-
dent mechanism [18]. Whether the LTCC window or NCX
has a dominant role in creating EADs depends on the disease
setting; it has been suggested that when oxygen radicals are
involved LTCC seems dominant, whereas in a β-adrenergic
setting NCX may be dominant [18]. Either way NCX and
LTCC are both important players in the generation of EADs.
In addition, an increase in INa-Late leads to higher [Na
+]i, which
pushes NCX in its reverse mode and Na+ is transported out
and Ca2+ into the cell, also leading to increased [Ca]i [19]. Via
the aforementioned mechanism, this in turn can lead to EAD
formation again, as is shown in Fig. 3.
Old strategies
Antiarrhythmic drugs are still classified according to the
Vaughan Williams classification. The underlying molecular
strategy includes class I: Na+ channel block, class II: β-
adrenergic receptor block, class III: K+ channel block, class
IV: Ca2+ channel block, and class V: Na+/K+ ATPase block
[20]. Drugs categorised into these various classes all have the
capability of terminating arrhythmias via different strategies.
These strategies are reviewed elsewhere [21]. Only class II
antiarrhythmic drugs, the β-adrenergic receptor blockers,
have proved to reduce mortality [21, 22]. One of the draw-
backs of the existing drugs is that most of them temper cardiac
performance leading to a negative haemodynamic effect in
patients. For example, class I drugs such as flecanide are used
in supraventricular arrhythmias but are negative inotropic and
also have proarrhythmic effects, which are likely due to ex-
cessive conduction slowing and reentry like tachyarrhythmias
[20, 21]. Class III drugs prolong the AP, thereby increasing the
refractory period, meanwhile terminating arrhythmias based
on short APDs such as atrial fibrillation. On the other hand,
APD prolongation is a well-established risk factor for long-
QTarrhythmias and can lead to ectopic activity through EADs
(Fig. 3). Class IV agents, due to their Ca2+ channel blocking
properties, have negatively inotropic, chronotropic, and
dromotropic effects. Class V agents such as digitalis lead to
high [Na+]i which will activate NCX thereby triggering
Ca2+overload, and associated ectopic activity (Fig. 3). New
antiarrhythmic strategies attempt to find ways to increase
antiarrhythmic efficacywhile relieving or omitting the adverse
side effects.
New targets for antiarrhythmic treatment
Drugs that interfere with CaMKII, NCX, RyR and its associ-
ated stabilising protein FKBP12.6, and the INa-Late are poten-
tial targets that are currently being investigated in order to
Fig. 4 a RyR open probability,
[Ca2+]SR, and sparks. Calcium
sparks occur when [Ca2+]SR
reaches RyR opening threshold.
RyR opening threshold is
influenced by the open
probability of RyR. Higher open
probability lowers the threshold.
[Ca2+]SR is affected by total
[Ca2+]in and SERCA. b In heart
failure [Ca2+]SR is lowered but the
RyR open threshold is lowered
more extensively rendering
[Ca2+]SR higher then threshold
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achieve clinical applicability. The focus is on interfering with
calcium handling of the cardiomyocytes and to become active
in the prevention or suppression of VTs. To date, interference
on SERCA has not resulted in drug candidates with potential
clinical applicability. Since SERCA function in heart failure is
considered to be depressed (as observed in several preclinical
models of heart failure), it is to note that a non-
pharmacological, but viral approach is currently under con-
sideration to restore SERCA function under conditions of
heart failure [23].
Acute modulation of antiarrhythmic targets
NCX
NCX and SERCA are the most important players during Ca2+
removal from the cytoplasm of the cardiomyocyte. During
depolarisation under physiological conditions, NCX contrib-
utesmarginally to the total inward Ca2+ current but most of the
time the channel is in its forward mode extruding Ca2+ from
the cell creating a Iti (proarrhythmic) [24].
NCX inhibition
Known inhibitors of NCX are KB-R7943 and SEA-0400.
However, KB-R7943 also inhibits LTCC, IK, and IK1 [25,
26], and thereby KB-R7943 is less specific than SEA-0400
(Table 1) [26]. Blocking NCX theoretically leads to Ca2+
accumulation and increased SR Ca2+ load, which in turn could
lead to adverse effects such as Ca2+ sparks [28]. Nonetheless,
due to the fact that SEA-0400 probably simultaneously in-
hibits LTCC, thereby inducing negative inotropic effects, this
counteraction possibly preserves cardiac output. Moreover,
NCX has a profound role in EAD formation (see section
above). Therefore, blocking of NCX potentially exerts antiar-
rhythmic effects [27]. Recently, our group showed that SEA-
0400 effectively prohibited torsades des pointes (TdP) ar-
rhythmia and EAD formation and, as important, without the
occurrence of the negative inotropic effects that are typically
observed when LTCC is blocked alone [27].
Antiarrhythmic approaches using NCX block do not, how-
ever, provide a uniform and straightforward answer about the
effectiveness of this strategy (Table 1). In ventricular
myocytes SEA-0400 showed different effects on EADs in
two different models, although it efficiently inhibited EADs
in both settings [18]. In another study, using canine isolated
Purkinje fibres, EAD amplitude and DAD incidence were also
suppressed by SEA-0400 [30]. Similarly, in Langendorff per-
fused rabbit hearts, SEA-0400 administration (in the presence
of sotalol or veratrinide in order to induce TdP) shortened
APD and the incidence of EADs [32], thereby reducing the
incidence of arrhythmias [33].
In contrast, in Langendorff perfused rabbit hearts, Farkas
et al. observed no antiarrhythmic effects when TdPs where
induced using dofetilide [31]. In guinea pigs, no effect of
SEA-0400 on arrhythmogeneity was found, and no effect on
AP configuration was noticed [35]. On the other hand, in
dogs, SEA-0400 did not change heart rate or blood pressure,
which are promising findings [27]. Moreover, a 2007 study
showed that SEA-0400 had no effects on inotropy and could
reverse the positive inotropic effects of Ouabain in isolated
guinea pig myocardium [33]. Nevertheless, no antiarrhythmic
outcome was found in ischaemia-reperfusion induced
arrhythmias.
Concerning safety, SEA-0400 decreased arrhythmias based
on intoxication with digitalis, but also caused AV block and
cardiac arrest in a small number of the dogs [34]. Due to lack
of consensus found in these results more research should be
performed before it can be concluded whether or not NCX
block has potency in clinical use.
RyR
RyR, and its function in cardiac physiology, has been exten-
sively reviewed by Kushnir and Marks [37–39]. Whether or
not RyR opens to release Ca2+ depends on the open probabil-
ity of RyR and the SR Ca2+ load, which are influenced via
various mechanisms, as described earlier.
RyR inhibition
Spontaneous release of Ca2+ by RyR is involved in the gen-
eration of triggered activity (Fig. 3a), and as such RyR is an
interesting target in antiarrhythmic therapy that would be
based on a decreased risk of DAD formation. This spontane-
ous release of Ca2+ is causative for arrhythmias as found in a
disease named catecholaminergic polymorphic ventricular
tachycardia (CPVT). Mutations in RyR can enhance the sus-
ceptibility for Ca2+ leak, especially under conditions with an
increased adrenergic drive. Flecainide, a well-established
class-Ic antiarrhythmic, showed additional and remarkable
efficacy to suppress these arrhythmias both in mice and
humans through enhancement of the threshold for triggered
activity [40, 41]. It remains to be discussed what the exact
contribution is of sodium channel block and RyR inhibition in
this preventive effect.
K201 (JTV-519) is a more recent compound that has been
tested as a potential inhibitor of RyR. It decreased spontane-
ous Ca2+ release at 1 μM by binding to FKBP12.6, thereby
increasing its affinity for RyR and stabilisation of the closed
conformation of RyRs [42, 43]. K201 has, however, various
other effects on different sarcolemmal ion channels (a multi-
channel blocker) [1], see Table 2. Previous experiments have
not been able to confirm consistent antiarrhythmic effects of
K201 (Table 2). Of the positive studies, K201 prevented the
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frequency of spontaneous APs after Ouabain in mice with the
RyR R4496C+/− mutation [49]. Wehrens et al. showed that
when FKBP12.6+/− mice were treated with K201 no arrhyth-
mias could be recorded, which was in contrast to non-treated
animals that regularly showed SCD [42]. On the other hand,
experiments on isolated cardiomyocytes or in intact RyR2
R4496C knock-in mice, elicited no decrease in DAD inci-
dence upon K201 administration [52]. In the CAVB (chronic
AV block) dog, K201 was not able to decrease the incidence
nor the severity of dofetilide-induced TdP. In addition, K201
prolonged repolarisation and slowed heart rate, although no
negative inotropic effects were observed [48]. These divergent
results are in contrast with the well-established molecular role
of RyR in the incidence of Ca2+ sparks and DADs and its
suppression by K201.
In the mentioned dog study, our group showed that at a
relatively high dose (1.5–2 μM), even proarrhythmic effects
of the drug were observed [48]. Although K201 has already
been used in clinical trials for treatment of atrial fibrillation
(AF), the results seem disappointing: only one has been com-
pleted without publication of the results, and two other trials
were prematurely terminated.
Other drugs are currently being tested or designed to allow
continuation of targeting RyR. Carvedilol, a registered β-
blocker, also blocks RyR and prevents spontaneous Ca2+
release at doses higher than needed for its β-blocking activity.
In this respect, the development of the carvedilol analogue
VK-II-86 has to be mentioned since it shows an enhanced
specificity regarding the RyR blocking capacities. It has been
suggested that in combination with a potent β-blocker, this
could be a promising antiarrhythmic approach although thus
far no further studies have been published using these com-
pounds in order to test their efficacy [54].
CaMKII
Besides its activation under pathological conditions through
oxidation by reactive oxygen species (ROS), activation of
CaMKII is mainly facilitated by CaM, a small cytoplasmic
protein. CaM needs to bind cytosolic Ca2+ before CaMKII can
be activated [55]. For that, CaMKII activation is indirectly
dependent on [Ca2+]i, but due to its capability of autophos-
phorylation is not solely dependent on the rise and fall in
[Ca2+]i.. When phosphorylation of CaMKII has been accom-
plished, the enzyme becomes persistently active and therefore
the natural beat-to-beat fall in [Ca2+]i will not immediately
affect the enzymes’ activity. CaMKII has a central role in Ca2+
handling, influencing RyR, LTCC, and SERCA (Fig. 2). By
phosphorylating RyR, CaMKII increases the open probability
[12, 56]. LTCC phosphorylation by CaMKII leads to faster
recovery from inactivation [57], whereas the effect of CaMKII
on SERCA (via phosphorylation of PLN) leads to an in-
creased SR Ca2+ load. CaMKII activation leads to an increase
in [Ca2+]i and is therefore able to influence NCX by pushing it
into the forward mode which results in a depolarising current.
All of the above-mentioned actions are under physiological
conditions. During cardiac pathology CaMKII expression and
function is upregulated, which can trigger proarrhythmia via
induction of ectopic activity [58–60]. This makes it an inter-
esting target for antiarrhythmic intervention.
CaMKII inhibition
Up till now two CaMKII inhibitors are known, W7 and KN-
93. KN-93 is a compound that competes with CaM for the
binding site on CaMKII, and through this mode it inhibits
activation of CaMKII, with an IC50 of 370 nM [61]. However,
KN-93 also appears to act as a multi-channel blocker in
cardiomyocytes as is depicted in Table 3. W7 is actually an
inhibitor of CaM [74], and therefore considered to be an
indirect inhibitor of CaMKII as well as of other targets of
CaM (e.g. RyR, LTCC).
So far, CaMKII antagonists show promising experimental
results (Table 3). In genetically engineered Langendorff per-
fused mouse hearts, W7 and KN-93 suppressed VTs in almost
all mice. However, W7 appeared to prolong APD to a higher
degree than KN-93 which renders the use of the more specific
inhibitor KN-93 favourable in this setting [71]. In
Langendorff perfused rat hearts, KN-93 effectively sup-
pressed ventricular fibrillation (VF) without affecting APD
[67], and also lowered the incidence of premature beats oc-
curring after ischaemia reperfusion interventions [66]. Simi-
larly, VF induced by angiotensin II was prevented by KN-93
in 75% of the hearts [65]. Furthermore, KN-93 also prevented
the occurrence of EADs in Langendorff perfused rabbit hearts
[62], while W-7 decreased EAD as well as TdP incidence,
even though W-7 was not able to counteract the sotalol-
induced APD prolongation [70].
Looking at intact animal studies, CaMKII inhibition by
KN-93 was able to prevent isoproterenol-induced arrhythmias
[69], as well as in other experimental setups in mice, such as
aortic banding, where KN-93 also proved to be successful in
preventing VTs [68]. In rabbits, pretreatment with W-7
prevented methoxamine-induced TdP [72, 73], and had no
undesirable effects on haemodynamics [73]. In CAVB dogs,
W-7 was successful in terminating dofetilide-induced TdP in
the majority of dogs [36]. Given its antiarrhythmic potency,
the minimal effects on APD and the fact that haemodynamics
were virtually unaffected, CaMKII inhibition might be a
favourable approach when compared with the old antiarrhyth-
mic strategies.
Late inward sodium current
The total inward sodium current is composed of a peak and
late component and is provided through voltage-gated Na
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channels in the sarcolemma, which are rapidly activated and
inactivated. Under physiological conditions, the INa-Late has a
much smaller amplitude than peak INa. Under pathological
circumstances, however, the INa -Late can be elevated up to 5
times, and substantially affect total INa leading to accumula-
tion of Na+ in the cytosol [75]. On its own, increased [Na]i
leads to APD prolongation, and by pushing NCX in the
reverse mode it can lead to increased [Ca2+]i, and triggered
arrhythmias.
Late INa inhibition
Due to its previously described role in arrhythmias, inhibition
of INa-Late is a topic of interest because it can possibly prevent
EAD and DAD triggered activity. Ranolazine is a well-known
inhibitor of INa-Late but its actions are not restricted to this
channel as it evokesmultiple other effects (Table 4). In Table 5,
we have listed its antiarrhythmic properties. In Langendorff
perfused guinea pig hearts, ranolazine abolished and
prevented ATX-II induced (pro) arrhythmic features on
APD, EADs and VTs in the ‘LQT-3 syndrome’ [84]. In guinea
pig isolated ventricular myocytes, ranolazine was able to
counteract the arrhythmic effects, such as APD prolongation
and subsequent EAD formation [82, 86]. In canine wedge
preparations, ranolazine also effectively prevented TdP and
EADs [76], and in rats it showed various antiarrhythmic
properties [77, 80, 85]. Even in clinical trials, ranolazine
showed its capability of reducing arrhythmic events [81].
Ranolazine is already being prescribed to treat patients with
chronic angina and, importantly, in a clinical trial a significant
decrease in the occurrence of ventricular arrhythmias was
observed compared to controls [81].
Recently, data have been published which suggest that
sophocarpine also possesses INa-Late inhibiting potency next
to its effect on other currents (IKr, ICa) [90]. GS-967 is another
new compound that is proposed to inhibit late INa,late specif-
ically (it affects peak INa and IKr only weakly at much higher
doses). This new compound has been tested in animal models
with positive findings [87, 88], which makes it an interesting
and potentially antiarrhythmic compound for future testing in
a clinical setting.
Conclusion
Old antiarrhythmic strategies, though proven clinically effec-
tive, have important drawbacks such as negative haemody-
namic effects and a small safety margin, thereby prohibiting
the use of higher dosages [21]. To improve specificity and
efficacy of pharmacological intervention, there is a continuous
quest for new pharmacological targets. Calcium handling
within the cardiomyocytes is such an important target since
disturbed calcium handling has a maladaptive and dual effect
that leads to both an increased propensity to develop arrhyth-
mias and to induction of contractile dysfunction. In the current
study we have reviewed the recent investments made to target
NCX, RyR, CaMKII and the late sodium current, all being
involved in proarrhythmia due to disturbed calcium handling.
Figure 5 provides a schematic overview of the current knowl-
edge regarding the potency and potential efficacy of drugs
affecting these new antiarrhythmic targets.
NCX So far, blocking of NCX, using SEA-0400, appears to
be neutral on inotropy due to the counteracting effects of 1)
anticipated positive inotropy by NCX block alone and 2)
negative haemodynamics by its additional inhibition of LTCC
[27, 36]. Taking into account that this compound is possibly
totally specific for NCX, it shows a neutral haemodynamic
effect but so far did not prove to be antiarrhythmic in all
experimental studies. The pharmacological industry has no
plans for further exploration in this direction and therefore the
future of this drug as an antiarrhythmic agent is uncertain.
Development of new NCX blockers is, however, foreseen and
could become tools for future clinical applicability.
RyR The antiarrhythmic potential of RyR block remains de-
batable, as positive results of K201 are scarce and
counteracted by negative results (Table 2). Together with the
possible proarrhythmic effects at the high dosage that is re-
quired for treatment of atrium fibrillation, the lack of convinc-
ing antiarrhythmic results, and various effects on other ion
currents, K201 may not be the best suitable future
antiarrhythmic agent. For this reason, development of a
more selective inhibitor is required to assess its antiar-
rhythmic properties.
Table 4 Ranolazine effects on
ion currents in cardiomyocytes Target Action Model Dose Block Author
Late INa Inhibition Canine wedge preparations 6 μmol/L 50 % Antzelevitch 2004 [76]
Late ICa Inhibition Canine wedge preparations 2–6 μmol/L 25–30 % Antzelevitch 2004 [76]
Iks Inhibition Canine wedge preparations 30 μmol/L 17 % Antzelevitch 2004 [76]
INa-Ca Inhibition Canine wedge preparations 50 μmol/L 50 % Antzelevitch 2004 [76]
Ikr Inhibition Canine wedge preparations 12 μmol/L 50 % Antzelevitch 2004 [76]
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CaMKII In Table 3, studies on CaMKII inhibition using either
W-7 or KN-93 in intact animals and Langendorff perfused
hearts are summarised, mostly showing a profound antiar-
rhythmic effect of the drugs. Also in various experimental
settings using isolated cardiomyocytes, the antiarrhythmic
properties of CaMKII inhibition are readily observed [36,
91]. Additionally important, blocking CaMKII provides
antihypertrophic effects and maintenance of LV function [1].
The clinical use ofW-7 and KN-93 is still under consideration.
The currently used and obviously attractive drugs are not
completely target specific, and long-term inhibition of
CaMKII with these drugs induces neurotoxicity [92] which
makes them less favourable [93]. Current development of new
entities by several industries is expectantly awaited by the
scientific community.
Late INa inhibition The use of ranolazine has also shown
positive results: prevention and suppression of EADs, and
VT/VF in several experimental approaches. Important aspect
is that the drug is already registered and clinically applicable.
Its antiarrhythmic efficacy is not complete, which opens the
road for improvement using this approach. In this line of
intervention, promising new drugs such as sophocarpine and
GS-967 are being investigated.
Overall, regardless of the current possibilities for pharma-
cological interventions, it is clear that new strategies will be
Fig. 5 Schematic overview of
experimental approaches that
have been performed to test
efficacy and antiarrhythmic
potency of drugs targeting NCX,
RyR, CamKII and late INa.
References are stated behind the
model. S stands for suppressive, P
stands for preventive. Asterisk
indicates papers in which no
plasma concentration was
measured. Dagger indicates
model in which proarrhythmic
events were observed
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welcome to prevent SCD due to arrhythmias. The new targets
discussed here prove to be interesting strategies for the future
and provide food for thought. Obviously, more research with
respect to the long-term effects of chronically blocking each of
the discussed targets is essential before research can proceed
to a more clinical setting.
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